Get the Stockscreener App
14.72
2.90%
-0.44
Mink Therapeutics Inc stock is traded at $14.72, with a volume of 82,831.
It is down -2.90% in the last 24 hours and up +100.56% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$15.16
Open:
$16.05
24h Volume:
82,831
Relative Volume:
0.09
Market Cap:
$58.67M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-20.16
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-20.69%
1M Performance:
+100.56%
6M Performance:
+60.70%
1Y Performance:
+63.92%
1-Day Range:
$14.36
$16.05
1-Week Range:
$14.36
$19.61
52-Week Range:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
14.72 | 60.42M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
What are MiNK Therapeutics Inc. company’s key revenue driversMarket Forecast Picks That Work - jammulinksnews.com
Why is MiNK Therapeutics Inc. stock attracting strong analyst attentionReal Time Opportunities Backed By Experts - jammulinksnews.com
Is now a turning point for MiNK Therapeutics Inc.Equity Forecast with Predictive AI Screener - Newser
Real time alert setup for MiNK Therapeutics Inc. performanceMarket Correction Proof Stock Screening Analysis - Newser
What is MiNK Therapeutics Inc. company’s growth strategyFree Stock Alerts For Every Investor - jammulinksnews.com
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - 富途牛牛
What are the latest earnings results for MiNK Therapeutics Inc.Financial News Guidance For Beginners - jammulinksnews.com
What makes MiNK Therapeutics Inc. stock price move sharplySafe Entry Screening with Data Backed Analysis - Newser
Chart overlay techniques for tracking MiNK Therapeutics Inc.Reversal Signal Prediction Based on Volume - Newser
MiNK Therapeutics Inc. Matches Institutional Buying FilterTrade Insight With Community Collaboration Supported - metal.it
MiNK Therapeutics Inc. Outperforms Peers on Volume MetricsPotential Breakout Stock List Published This Week - metal.it
What high frequency data says about MiNK Therapeutics Inc.Trade Alert System with Volume Analysis - Newser
Is it the right time to buy MiNK Therapeutics Inc. stockPost Market Watchlist For Every Investor - jammulinksnews.com
RSI Suggests Rebound May Be Near in MiNK Therapeutics Inc.Entry and Exit Strategy Optimizer Tool Tested - metal.it
MiNK Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers Say Predictive Screener for Daily Trade Watch - metal.it
How volatile is MiNK Therapeutics Inc. stock compared to the marketInvest confidently with data-driven strategies - jammulinksnews.com
What are analysts’ price targets for MiNK Therapeutics Inc. in the next 12 monthsMaximize your portfolio’s growth with expert tips - jammulinksnews.com
What catalysts could drive MiNK Therapeutics Inc. stock higher in 2025Get exclusive access to premium stock research - jammulinksnews.com
MiNK Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingShort Term Profit Focus - Newser
MiNK Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it
Why MiNK Therapeutics Inc. stock attracts strong analyst attentionCapital Growth Picks - Newser
Competitive Positioning of MiNK Therapeutics Inc.: Is It Leading or LaggingFree Investment Community - Newser
Will MiNK Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsCapital Protected Stock Selections - Newser
Is MiNK Therapeutics Inc. a good long term investmentConsistent wealth multiplication - PrintWeekIndia
What analysts say about MiNK Therapeutics Inc. stockExplosive market performance - PrintWeekIndia
What drives MiNK Therapeutics Inc. stock priceFree Advanced Stock Screener Access - PrintWeekIndia
MiNK Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Autocar Professional
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
How MiNK Therapeutics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
MiNK Therapeutics (NASDAQ:INKT) Upgraded at B. Riley - Defense World
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):